What is Celldex Therapeutics Inc (CLDX) stock price today?

Celldex Therapeutics Inc (CLDX) currently trades at $33.97 per share. The stock has a market capitalization of $2.62B and a P/E ratio of —x.

Is CLDX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Celldex Therapeutics Inc has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Celldex Therapeutics Inc's revenue and earnings?

Celldex Therapeutics Inc has trailing twelve-month (TTM) revenue of $1.54M with profit margins of 0.00%. Earnings per share (EPS) is $-3.90.

CLDX

Celldex Therapeutics Inc

NASDAQ: CLDX · HEALTHCARE · BIOTECHNOLOGY

$33.97

+1.95% today

Updated 2026-05-08

Market cap

$2.62B

P/E ratio

—

P/S ratio

1,692.71x

EPS (TTM)

$-3.90

Dividend yield

—

52W range

$18 – $36

Volume

1.0M

Market cap

$2.62B

P/E ratio

—

P/S ratio

1,692.71x

EPS (TTM)

$-3.90

Dividend yield

—

52W range

$18 – $36

Volume

1.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →195 stocks currently score above 75

Price targets

Analyst target

$57.00

+67.80%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy12 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-65.59M

- Revenue declining -89.70% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$2.36M	$6.88M	$7.02M	$1.50M	$1.54M
Net income	$-112.33M	$-141.43M	$-157.86M	$-258.80M	$-78.69M
EPS	—	—	—	—	$-3.90
Free cash flow	$-105.56M	$-109.11M	$-159.70M	$-213.66M	$-65.59M
Profit margin	-4,765.59%	-2,054.76%	-2,248.76%	-17,253.33%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CLDX	$2.62B	22	2.7	2.5	5.0	5.0	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-38.45%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-20.52%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+42.20%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Celldex Therapeutics Inc trades at $33.97. Our Smart Value Score of 22/100 indicates the stock is weak. TTM revenue stands at $1.54M.

Frequently asked questions

What is Celldex Therapeutics Inc's stock price?

Celldex Therapeutics Inc (CLDX) trades at $33.97.

Is Celldex Therapeutics Inc overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Celldex Therapeutics Inc (CLDX)?

The analyst target price is $57.00, representing +67.8% upside from the current price of $33.97.

What is Celldex Therapeutics Inc's revenue?

TTM revenue is $1.54M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1,692.71x

ROE-40.60%

Beta0.98

50D MA$31.75

200D MA$26.78

Shares out0.08B

Float0.06B

Short ratio—

Avg volume1.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CLDX vs LLY →CLDX vs JNJ →CLDX vs ABBV →Stock screener →